Loading...
XNAS
DXCM
Market cap28bUSD
Jul 09, Last price  
73.02USD
1D
-1.40%
1Q
14.06%
Jan 2017
389.25%
IPO
2,749.56%
Name

Dexcom Inc

Chart & Performance

D1W1MN
XNAS:DXCM chart
P/E
33.69
P/S
6.04
EPS
2.17
Div Yield, %
—
Shrs. gr., 5y
0.78%
Rev. gr., 5y
19.33%
Revenues
4.66b
+15.60%
2,169,7904,627,0009,838,00029,693,00048,631,00076,266,00099,900,000160,000,000259,200,000402,000,000573,300,000718,500,0001,031,600,0001,476,000,0001,926,700,0002,448,500,0002,909,800,0003,622,300,0004,033,000,0004,662,000,000
Net income
836m
+45.14%
-46,599,291-45,878,000-55,184,000-53,524,000-55,170,000-44,746,000-54,500,000-29,800,000-22,400,000-57,600,000-65,600,000-50,200,000-127,100,000101,100,000493,600,000216,900,000341,200,000541,500,000576,200,000836,300,000
CFO
1.44b
+45.60%
-43,734,840-33,207,000-37,451,000-39,389,000-42,676,000-30,126,000-33,100,0002,400,00023,600,00049,000,00056,200,00092,000,000123,200,000314,500,000475,600,000442,500,000669,500,000748,500,000989,500,0001,440,700,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
URL
https://www.dexcom.com/
IPO date
Apr 14, 2005
Employees
7,500
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT